
GRI Stock Forecast & Price Target
GRI Analyst Ratings
Bulls say
GRI Bio is an innovative clinical-stage biotech company with a promising product pipeline, including GRI-0621, a small molecule RAR-beta and gamma dual agonist for the treatment of diseases associated with dysregulated immune responses. With positive top-line data in December 2025 and a current Phase 2a trial in patients with IPF, the company's potential for success in this large market is attractive. In addition, the recent Q3 results show strong financial management and potential for continued growth.
Bears say
GRI Bio is a clinical-stage biotech company with potential drugs targeting multiple serious diseases, but the current valuation is attractive due to long development and commercialization timelines and the company's financials are not yet generating any revenue. While the company's two drugs present high risks, their estimated billion-dollar market potential makes them attractive long-term investments in the autoimmune and inflammatory disorder space, especially their lead candidate GRI-0803 which aims to treat the estimated 1.5 million Americans with lupus.
This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GRI Analyst Forecast & Price Prediction
Start investing in GRI
Order type
Buy in
Order amount
Est. shares
0 shares